Home » Topics » Disease categories and therapies » Musculoskeletal

Musculoskeletal
RSS

Advisory committee recommends approval of Celebrex for arthritis and further discussions for pain

Dec. 2, 1998

Dual 5-LO/COX inhibitor from Eisai displays potent antiinflammatory efficacy in vivo

Dec. 1, 1998

Results published from phase II trial of Immune Response's rheumatoid arthritis treatment

Dec. 1, 1998

LTA4 hydrolase inhibitors reported in development at Santen

Nov. 30, 1998

FDA advisory committee meets this week to discuss Celebrex NDA

Nov. 30, 1998

Immunex files sBLA for Enbrel as treatment for juvenile rheumatoid arthritis

Nov. 27, 1998

British Biotech expands pipeline of MMP inhibitors

Nov. 27, 1998

Amarillo Biosciences initiates phase III clinical trial with oral interferon alfa

Nov. 27, 1998

Merck & Co. synthesizes potent and orally active p38 inhibitor

Nov. 25, 1998

COX-2-specific inhibitor from Merck filed for approval with FDA

Nov. 24, 1998

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026